drugset

drugset / Trial / NCT03268889

Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)

NCT03268889 ↗

Unknown 39 enrolled The First Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy and safety of Chidamide plus CHOP regimen for de novo PTCL patients.

Timeline

Start: 2017-06-15
Primary completion: 2020-06-15
Completion: 2020-09-15

Publications

Zong X, Yang Z, Zhou J, Jin Z, Wu D. Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma. Front Immunol. 2024 Aug 20;15:1430648. doi: 10.3389/fimmu.2024.1430648. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tucidinostat	Small molecule	30 mg	Oral

Indications